Moolchan ET - Search Results

1

Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.

Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Huestis MA, et al. Among authors: moolchan et. Arch Gen Psychiatry. 2001 Apr;58(4):322-8. doi: 10.1001/archpsyc.58.4.322. Arch Gen Psychiatry. 2001. PMID: 11296091 Clinical Trial.

2

The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers.

Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Huestis MA. Gorelick DA, et al. Among authors: moolchan et. Am Heart J. 2006 Mar;151(3):754.e1-754.e5. doi: 10.1016/j.ahj.2005.11.006. Am Heart J. 2006. PMID: 16504646 Clinical Trial.

3

Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers.

Schepers RJ, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA. Schepers RJ, et al. Among authors: moolchan et. Clin Chem. 2003 Jan;49(1):121-32. doi: 10.1373/49.1.121. Clin Chem. 2003. PMID: 12507968 Clinical Trial.

4

Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans.

Gustafson RA, Levine B, Stout PR, Klette KL, George MP, Moolchan ET, Huestis MA. Gustafson RA, et al. Among authors: moolchan et. Clin Chem. 2003 Jul;49(7):1114-24. doi: 10.1373/49.7.1114. Clin Chem. 2003. PMID: 12816908 Clinical Trial.

5

Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans.

Kim I, Oyler JM, Moolchan ET, Cone EJ, Huestis MA. Kim I, et al. Among authors: moolchan et. Ther Drug Monit. 2004 Dec;26(6):664-72. doi: 10.1097/00007691-200412000-00013. Ther Drug Monit. 2004. PMID: 15570192 Clinical Trial.

6

Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.

Goodwin RS, Gustafson RA, Barnes A, Nebro W, Moolchan ET, Huestis MA. Goodwin RS, et al. Among authors: moolchan et. Ther Drug Monit. 2006 Aug;28(4):545-51. doi: 10.1097/00007691-200608000-00010. Ther Drug Monit. 2006. PMID: 16885723 Clinical Trial.

7

Cannabinoid concentrations in hair from documented cannabis users.

Huestis MA, Gustafson RA, Moolchan ET, Barnes A, Bourland JA, Sweeney SA, Hayes EF, Carpenter PM, Smith ML. Huestis MA, et al. Among authors: moolchan et. Forensic Sci Int. 2007 Jul 4;169(2-3):129-36. doi: 10.1016/j.forsciint.2006.08.005. Epub 2006 Sep 11. Forensic Sci Int. 2007. PMID: 16963215 Free PMC article. Clinical Trial.

8

Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray.

Myers CS, Taylor RC, Moolchan ET, Heishman SJ. Myers CS, et al. Among authors: moolchan et. Neuropsychopharmacology. 2008 Feb;33(3):588-98. doi: 10.1038/sj.npp.1301425. Epub 2007 Apr 18. Neuropsychopharmacology. 2008. PMID: 17443125 Clinical Trial.

9

Interest in marijuana treatment programs among teenage smokers and nonsmokers.

Sheer AJ, Gorelick DA, Collins CC, Schroeder JR, Heishman SJ, Leff MK, Moolchan ET. Sheer AJ, et al. Among authors: moolchan et. J Subst Abuse Treat. 2009 Dec;37(4):421-5. doi: 10.1016/j.jsat.2009.04.007. Epub 2009 Jun 24. J Subst Abuse Treat. 2009. PMID: 19556094 Free PMC article.

10

Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: plasma and saliva analysis.

Moolchan ET, Cone EJ, Wstadik A, Huestis MA, Preston KL. Moolchan ET, et al. J Anal Toxicol. 2000 Oct;24(7):458-66. doi: 10.1093/jat/24.7.458. J Anal Toxicol. 2000. PMID: 11043647

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

114 results

Search Page